Latest News

Novel anti-CD20 monoclonal approved in Canada for MS


Ofatumumab (Kesimpta), a new anti-CD20 monoclonal antibody, has received approval from Health Canada for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with active disease defined by clinical and imaging features. In clinical trials, active disease was defined as at least one relapse or one Gd-enhancing lesion in the previous year.

Read More


COVID vaccine guidance for MS patients


The Canadian Network of MS Clinics has endorsed a COVID vaccination guidance document developed by the U.S. National MS Society (see links below). The advice is based on expert opinion due to a lack of data on the safety and efficacy of the COVID vaccine in the multiple sclerosis population and applies only to the mRNA vaccines (Pfizer, Moderna) currently available.

Read More